Innovative Technology Acquisition said this week it will begin marketing and distributing the first dietary supplement developed by its subsidiary BioSource Therapeutics, during the first quarter of 2003.
Nutraplete is said to help immune-compromised individuals with conditions including HIV/AIDS, hepatitis C, and cancer. It is billed as a functional food that helps to regulate the body's pro-oxidant balance, restore lean muscle mass that results from catabolism/wasting syndrome and support the viability of the immune system.
The company said the supplement would typically be used to reduce the side effects of the HAART drug regimen, taken by HIV patients, and other treatments. The therapeutic nutritional supplement could help strengthen their immune resources and contribute to a better quality of life.
BST is hoping that Nutraplete will be prescribed by physicians and covered under Medicaid. Initially, Nutraplete will be marketed under the Medicaid program in New Jersey, Connecticut and Nevada. Other target states include New York, Florida, Illinois, California and Texas. Many of these states will require BST to go through an application process in order to obtain approval for Nutraplete to be available through Medicaid.
Once Nutraplete is approved in targeted jurisdictions in the United States, BST will seek approval internationally, said the firm.
BioSource Therapeutics (BST) was bought by Innovative Technology (ITAQ) in November 2002. ITAQ has also developed a functional food containing the dietary supplement Virilite. The Terbo Bar with Virilite provides support for those suffering from decreased sex drive as a side effect of anti-depressants and other medications. ITAQ is currently reformulating the Terbo Bar in a capsule to conform with formulation advances of Virilite by its Norwegian manufacturer. The new version is expected to be available later in the year.